Christopher Kiritsy
Director/Board Member at PIERIS PHARMACEUTICALS, INC.
Net worth: 3 660 $ as of 2024-03-30
Profile
Christopher P.
Kiritsy is the founder of Arisaph Pharmaceuticals, Inc. (founded in 1999) and Precision Kapital LLC (founded in 2018).
At Arisaph Pharmaceuticals, he held the titles of President, Chief Executive Officer & Director from 2005 to 2018.
He is currently a Director at HTG Molecular Diagnostics, Inc. (since 2022) and an Independent Director at Pieris Pharmaceuticals, Inc. (since 2016).
He previously held positions such as Chairman at Avaxia Biologics, Inc., Associate Director-Product Development at the University of Oregon, Director at Melinta Subsidiary Corp., and CFO & Executive VP-Corporate Development at KOS Pharmaceuticals, Inc. Mr. Kiritsy holds an MBA from Boston University and an undergraduate degree from Bowdoin College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-06-20 | 20,000 ( 0.02% ) | 3 660 $ | 2024-03-30 | |
| 2023-02-28 | 0 ( -.--% ) | - $ | 2024-03-30 |
Christopher Kiritsy active positions
| Companies | Position | Start |
|---|---|---|
| PIERIS PHARMACEUTICALS, INC. | Director/Board Member | 2016-09-19 |
| HTG MOLECULAR DIAGNOSTICS, INC. | Director/Board Member | 2022-01-26 |
| Precision Kapital LLC | Founder | 2017-12-31 |
Former positions of Christopher Kiritsy
| Companies | Position | End |
|---|---|---|
Arisaph Pharmaceuticals, Inc.
 Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Founder | 2017-12-31 |
KOS Pharmaceuticals, Inc.
 KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Director of Finance/CFO | 2005-05-22 |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Director/Board Member | - |
| University of Oregon | Corporate Officer/Principal | - |
Avaxia Biologics, Inc.
 Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Chairman | - |
Training of Christopher Kiritsy
| Boston University | Masters Business Admin |
| Bowdoin College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Health Technology |
Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Health Technology |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Health Technology |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
| Precision Kapital LLC |
- Stock Market
- Insiders
- Christopher Kiritsy
